Last updated on August 2019

Neratinib HER Mutation Basket Study (SUMMIT)

Brief description of study

This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.

Detailed Study Description

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification.

The trial will consist of a screening period, a treatment period, and an end of treatment visit occurring when neratinib is discontinued for any reason, a safety follow-up visit occurring 28 to 42 days after the last dose of neratinib and a survival follow-up period lasting for a maximum of 12 months for each patient after their last dose of neratinib or until initiation of additional anti-cancer therapy.

Clinical Study Identifier: NCT01953926

Find a site near you

Start Over

University of Southern California

Los Angeles, CA United States
  Connect »

Mayo Clinic Arizona

Phoenix, AZ United States
  Connect »

City of Hope

Duarte, CA United States
  Connect »

Stanford Cancer Center

Palo Alto, CA United States
  Connect »

Mayo Clinic Florida

Jacksonville, FL United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Ochsner Clinic Foundation

New Orleans, LA United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

MMCORC Health Partners

Saint Louis Park, MN United States
  Connect »

Washington University

Saint Louis, MO United States
  Connect »

Kettering Medical Center

Kettering, OH United States
  Connect »

The West Clinic

Germantown, TN United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »


La Crosse, WI United States
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Royal Free Hospital

London, United Kingdom
  Connect »